English
Back
Download
Log in to access Online Inquiry
Back to the Top
avatar
Stock Region wrote a post · Jul 10, 2024 02:34

Clinical-stage Biopharmaceutical Company Announces Negative Results From Clinical Study

HilleVax, Inc. Announced Disappointing Results from NEST-IN1 Clinical Study.
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further development of its HIL-214 vaccine in infants. $HilleVax (HLVX.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
5199 Views
Comment
Sign in to post a comment
    avatar
    Stock Region
    255
    Followers
    0
    Following
    537
    Visitors
    Follow

    Market Insights

    Market Hot Picks Market Hot Picks
    No. Symbol Price
    Tesla
    TSLA
    268.460
    NVIDIA
    NVDA
    110.150
    Newsmax
    NMAX
    233.000
    4
    CoreWeave
    CRWV
    52.570
    5
    Palantir
    PLTR
    84.680
    Log In for the Full List
    Unlock Now

    Trump's comeback to the Office

    Following Trump's Policies to Seek Investment Opportunities

    Monetary Policy: Navigating the Fed's Rate Cut Cycle

    Changing Fed policy is altering the market math for investors.

    Reassessing Chinese Assets

    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.

    - No more -